Filing Analysis
Range Impact, Inc. has adopted new bylaws effective November 7, 2024. The amendments primarily serve to reflect the company's new name and clarify jurisdiction for securities-related legal actions.
📋 Key Facts
- The Board of Directors adopted new Bylaws on November 7, 2024.
- Amendments include a change to reflect the Company's new name: Range Impact, Inc.
- Bylaws were amended to clarify that 'exclusive forum' provisions do not apply to claims arising under the Securities Act of 1933 or the Securities Exchange Act of 1934.
Range Impact, Inc. has announced that its previously issued unaudited condensed consolidated financial statements for the quarter ended March 31, 2024, should no longer be relied upon due to an accounting error regarding a vendor invoice.
🚩 Red Flags
- Restatement of previously issued financial statements (Item 4.02).
- Admission of material weakness in internal control over financial reporting.
- Disclosure that disclosure controls and procedures were not effective at the time of original issuance.
📋 Key Facts
- The company identified a $462,691 subcontractor invoice from March 2024 that was incorrectly posted in April 2024.
- This error resulted in understated expenses and overstated net income for the Q1 period ended March 31, 2024.
- Net loss for the quarter ended March 31, 2024 increased from $751,149 to $1,213,840 due to the restatement.
- Total liabilities as of March 31, 2024 increased from $11,993,151 to $12,455,842.
- The company filed a Form 10-Q/A on August 8, 2024, to amend and restate the financial statements.
Range Impact, Inc. has entered into an agreement to sell its wholly-owned subsidiary, Graphium Biosciences, Inc., which contains all of the company's legacy cannabinoid drug development assets and intellectual property.
🚩 Red Flags
- Related-party transaction: The purchaser is controlled by former officers of the company (Dr. Brandon Zipp and Mr. Richard McKilligan).
- Asset stripping: The company is disposing of its primary legacy drug development assets/intellectual property.
- Low cash consideration: The deal relies heavily on warrants in a third-party entity rather than immediate liquid cash.
📋 Key Facts
- Date of transaction: September 30, 2024
- Purchaser: Placer Biosciences, Inc. (owned/controlled by former officers Dr. Brandon Zipp and Mr. Richard McKilligan)
- Assets sold: All common stock of Graphium Biosciences, Inc., including IP, permits, and lab equipment for cannabinoid-based therapeutics.
- Consideration: A warrant to exchange for 1,000 shares of Placer Biosciences (approx. 25% of its outstanding common stock) exercisable at $0.01/share; de minimis cash; and 50% of equipment sale proceeds over the next 12 months.
- The subsidiary Graphium was not considered a 'significant subsidiary' under Regulation S-X.
Range Impact, Inc. is exiting its Abandoned Mine Land (AML) business line by selling substantially all real and personal property of its subsidiary, Collins Building & Contracting, Inc. The transaction serves to settle $2.94 million in outstanding debt owed to the buyer.
🚩 Red Flags
- Related-party transaction: The assets were sold to entities owned by Roger L. Collins Jr., the former President of the subsidiary.
- Debt settlement via asset sale: The company is effectively trading its core AML business assets to extinguish $2.94M in debt rather than using cash flow or new equity.
- Strategic pivot/retreat: The exit from a line of business acquired only one year prior (August 2023) suggests the previous expansion strategy failed to meet expectations.
📋 Key Facts
- Date of agreement: August 22, 2024.
- Transaction value: Full cancellation and discharge of $2,940,836 in principal and accrued interest on two promissory notes.
- Assets sold include a mechanic shop, land, stone quarry (Braxton County, WV), vehicles, equipment, and supplies.
- The buyer consists of entities owned and controlled by Roger L. Collins Jr., the former President of Collins Building.
- Strategic rationale: Exit AML business to focus capital on reclamation/repurposing of Company-owned mine sites.
Range Impact, Inc. filed an 8-K to announce the release of its financial results for the second quarter of 2024 via a press release.
📋 Key Facts
- The company issued a press release on August 14, 2024, regarding Q2 2024 financial results.
- The filing is made pursuant to Item 8.01 (Other Events).
- Financial results are contained in Exhibit 99.1.
Range Impact, Inc. entered into a securities purchase agreement with Continental Heritage Holding Company LLC to issue 3,703,704 shares of common stock at $0.27 per share. The transaction closed on June 18, 2024, providing approximately $1,000,000 in gross proceeds.
🚩 Red Flags
- Significant dilution: Issuance of over 3.7 million shares at a low price point ($0.27/share).
- Potential for future dilution: Company is obligated to use commercially reasonable efforts to register these shares, which will likely lead to an S-1 filing and increased float.
- Micro-cap financing profile: The transaction is structured as a private placement (Regulation D) typical of companies seeking immediate liquidity.
📋 Key Facts
- Date of agreement: June 17, 2024
- Closing date: June 18, 2024
- Purchaser: Continental Heritage Holding Company LLC (Florida LLC)
- Number of shares issued: 3,703,704 common shares
- Price per share: $0.27
- Aggregate gross proceeds: approximately $1,000,000
- Exemption used: Section 4(a)(2) and Rule 506 of Regulation D (Accredited Investor)
Range Impact, Inc. filed an 8-K to announce the release of its financial results for the first quarter of 2024 via a press release.
📋 Key Facts
- The company issued a press release on May 15, 2024, regarding Q1 2024 financial results.
- The filing is made under Item 8.01 (Other Events) and includes Exhibit 99.1.
- The report was signed by CEO Michael Cavanaugh.
Range Impact, Inc. announced a restructuring of its leadership team effective April 25, 2024. The company appointed Patricia Missal as CFO and transitioned both the former CFO and the Chief Science Officer to focus exclusively on its subsidiary, Graphium Biosciences, Inc.
🚩 Red Flags
- Significant management shift: Two key officers (CFO and CSO) are being moved from the parent company to focus solely on a subsidiary, suggesting a strategic pivot or isolation of the subsidiary's operations.
- The mention of 'restructuring' in Item 8.01 often correlates with cost-cutting or organizational shifts that can precede financial volatility.
📋 Key Facts
- Patricia Missal (CPA) appointed as Chief Financial Officer, effective April 25, 2024.
- Richard McKilligan transitions from Company CFO/Counsel/Secretary to serve only as CFO of subsidiary Graphium Biosciences, Inc.
- Dr. Brandon Zipp transitions from Company CSO to serve exclusively as CSO of Graphium Biosciences, Inc.
- Ms. Missal's compensation includes a $225,000 annual base salary and 250,000 stock options vesting over one year.
- The filing references a broader restructuring of the subsidiary Graphium.
Range Impact, Inc. filed an 8-K to announce the release of its financial results for the fourth quarter and full fiscal year 2023.
📋 Key Facts
- The company issued a press release on March 29, 2024, regarding FY 2023 and Q4 2023 financial results.
- The filing incorporates the press release as Exhibit 99.1.
- Report date: March 29, 2024.